Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses

Current State of Clostridium difficile Treatment Options

(2012) A. A. Venugopal et al.   CLINICAL INFECTIOUS DISEASES

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

(2012) O. A. Cornely et al.   CLINICAL INFECTIOUS DISEASES

Burden of Clostridium difficile on the Healthcare System

(2012) Erik R. Dubberke et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin: A Macrocyclic Antibiotic for the Treatment ofClostridium difficileInfection

(2011) Jennifer S Hardesty et al.   PHARMACOTHERAPY

Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment ofClostridium difficileinfections

(2010) Ian R Poxton   Future Microbiology

Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin Production

(2010) M. Merrigan et al.   JOURNAL OF BACTERIOLOGY

The role of toxin A and toxin B in Clostridium difficile infection

(2010) Sarah A. Kuehne et al.   NATURE

Clostridium difficile infection: epidemiology, risk factors and management

(2010) Ashwin N. Ananthakrishnan   Nature Reviews Gastroenterology & Hepatology

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)

(2009) M.P. Bauer et al.   CLINICAL MICROBIOLOGY AND INFECTION

Clostridium difficile infection: new developments in epidemiology and pathogenesis

(2009) Maja Rupnik et al.   NATURE REVIEWS MICROBIOLOGY

Both Oral Metronidazole and Oral Vancomycin Promote Persistent Overgrowth of Vancomycin-Resistant Enterococci during Treatment of Clostridium difficile-Associated Disease

(2008) W. N. Al-Nassir et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY